Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

anges in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The third study in the Phase 3 program, a multi-center safety study, for which patient recruitment was completed in December 2008, is an ongoing open-label, single-armed study involving 529 patients in North America. The lead investigator is Joel Kaufman, M.D., Associate Clinical Professor in Urology at University of Colorado School of Medicine in Denver, Colorado and at Urology Research Options in Aurora, Colorado.

First efficacy results are expected during the third quarter of 2009 with an NDA filing targeted in 2010.

About Cetrorelix

Cetrorelix pamoate is an investigational agent that has shown in Phase 2 studies to provide fast and long lasting relief of BPH symptoms and was well tolerated, with a low incidence of sexual side effects. Cetrorelix is part of AEterna Zentaris' luteinizing hormone-releasing hormone (LHRH) antagonist therapeutic approach. This peptide-based active substance was developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan. It was launched on the market through Serono (now Merck Serono) in the U.S., Europe and in several other countries, as well as in Japan through Shionogi.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far from being completely understood. Data from ongoing research suggest BPH and lower uri
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... of Engineering at the University of Delaware, is ... in energy engineering, environmental sustainability and electronics. , ... rock with a well-defined, crystalline structure. At the ... decided that zeolites can separate molecules with size ... (one-tenth of a nanometer), making them useful to ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Your ... advances in modeling lithium-ion battery storage capacity. , ... from a theoretical model created at Lawrence ... that predicts how carbon components will perform ... storage emphasizes the urgent need for higher-performance batteries. ...
(Date:7/24/2014)... 24, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Sulphate basic information, including its definition, classification, ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis, ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... HARBIN, China, Feb. 24 /PRNewswire-Asia-FirstCall/ -- China ... or "the Company") (Nasdaq: CSKI ... over-the-counter,drugs in the People,s Republic of China ... Peng Lai Jin Chuang Pharmaceutical Company ("Jin,Chuang"), ...
... biotech company in Madison, Wisconsin is so concerned about ... that they have volunteered to give away free bottles ... the incoming administration who has forgotten to pay taxes ... government employees in positions of responsibility have many important ...
... -- Quarter Highlighted by Cinryze(TM) [C1 Inhibitor (human)] Commercial Launch ... VPHM ) reported today its financial results for the fourth ... 30, 2008 include:Operational: , , , ... Lev Pharmaceuticals, Inc. (Lev) in October 2008; , ...
Cached Biology Technology:China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 3Mental Stimulus Package: Government Officials who Forgot to Pay Taxes Will Receive Free Memory-boosting Supplement 2Mental Stimulus Package: Government Officials who Forgot to Pay Taxes Will Receive Free Memory-boosting Supplement 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12
(Date:7/25/2014)... congenital central nervous system disease that is caused ... during the embryonic phase. Many patients have varying ... neurocognitive retardation. Such problems decrease the patients, functional ... Ankara Physical Medicine and Rehabilitation Education and Research ... with SB, using the Pediatric Evaluation of Disability ...
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire-iReach/ -- ... managing data from cardiac devices, has cut emergency room ... the UC San Diego (UCSD) Medical Center, according to ... Journal. The UCSD Emergency Departments are using the suite ... such as pacemakers or defibrillators. "Using Geneva,s ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... Georgian town of Reepham in Norfolk are taking part in ... Anglia (UEA). Like two million homes across the ... warmth and hot water, and the aim of the UEA ... a viable option. The renewable fuel being used is ...
... a striking similarity between heart disease and Duchenne muscular ... that a new class of experimental drugs for heart ... At first glance, heart failure and the muscle-wasting ... usually before the age of 6, destroying their muscle ...
... GAITHERSBURG, Md.The bacterium behind one of mankind,s deadliest scourges, ... Institute of Standards and Technology (NIST) and the Department ... answering the decades-old question of what controls the switching ... of life,s functions. In a Journal of ...
Cached Biology News:Trailblazing rural community shows green heating oil a viable option 2While focusing on heart disease, researchers discover new tactic against fatal muscular dystrophy 2Long-sought protein structure may help reveal how 'gene switch' works 2Long-sought protein structure may help reveal how 'gene switch' works 3
Mouse anti human pro-Relaxin-2...
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... polyclonal to ErbB 2 - BSA ... for all tested applications). ... conjugated to KLH, corresponding to C ... c-ErbB2 Entrez GeneID: ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Biology Products: